These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

617 related items for PubMed ID: 26690702

  • 21. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia.
    Cui B, Ghia EM, Chen L, Rassenti LZ, DeBoever C, Widhopf GF, Yu J, Neuberg DS, Wierda WG, Rai KR, Kay NE, Brown JR, Jones JA, Gribben JG, Frazer KA, Kipps TJ.
    Blood; 2016 Dec 22; 128(25):2931-2940. PubMed ID: 27815263
    [Abstract] [Full Text] [Related]

  • 22. Critical role of Wnt5a-Ror2 signaling in motility and invasiveness of carcinoma cells following Snail-mediated epithelial-mesenchymal transition.
    Ren D, Minami Y, Nishita M.
    Genes Cells; 2011 Mar 22; 16(3):304-15. PubMed ID: 21342370
    [Abstract] [Full Text] [Related]

  • 23. Wnt5a-Ror2 signaling in mesenchymal stem cells promotes proliferation of gastric cancer cells by activating CXCL16-CXCR6 axis.
    Takiguchi G, Nishita M, Kurita K, Kakeji Y, Minami Y.
    Cancer Sci; 2016 Mar 22; 107(3):290-7. PubMed ID: 26708384
    [Abstract] [Full Text] [Related]

  • 24. MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia.
    Rassenti LZ, Balatti V, Ghia EM, Palamarchuk A, Tomasello L, Fadda P, Pekarsky Y, Widhopf GF, Kipps TJ, Croce CM.
    Proc Natl Acad Sci U S A; 2017 Oct 03; 114(40):10731-10736. PubMed ID: 28923920
    [Abstract] [Full Text] [Related]

  • 25. Wnt5a induces homodimerization and activation of Ror2 receptor tyrosine kinase.
    Liu Y, Rubin B, Bodine PV, Billiard J.
    J Cell Biochem; 2008 Oct 01; 105(2):497-502. PubMed ID: 18615587
    [Abstract] [Full Text] [Related]

  • 26. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis.
    Maeda K, Kobayashi Y, Udagawa N, Uehara S, Ishihara A, Mizoguchi T, Kikuchi Y, Takada I, Kato S, Kani S, Nishita M, Marumo K, Martin TJ, Minami Y, Takahashi N.
    Nat Med; 2012 Feb 19; 18(3):405-12. PubMed ID: 22344299
    [Abstract] [Full Text] [Related]

  • 27. High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia.
    Ghia EM, Rassenti LZ, Choi MY, Quijada-Álamo M, Chu E, Widhopf GF, Kipps TJ.
    Leukemia; 2022 Jun 19; 36(6):1609-1618. PubMed ID: 35418613
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling.
    Enomoto M, Hayakawa S, Itsukushima S, Ren DY, Matsuo M, Tamada K, Oneyama C, Okada M, Takumi T, Nishita M, Minami Y.
    Oncogene; 2009 Sep 10; 28(36):3197-208. PubMed ID: 19561643
    [Abstract] [Full Text] [Related]

  • 33. Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting.
    Karvonen H, Perttilä R, Niininen W, Hautanen V, Barker H, Murumägi A, Heckman CA, Ungureanu D.
    Oncogene; 2019 Apr 10; 38(17):3288-3300. PubMed ID: 30631148
    [Abstract] [Full Text] [Related]

  • 34. Structure and function of the ROR2 cysteine-rich domain in vertebrate noncanonical WNT5A signaling.
    Griffiths SC, Tan J, Wagner A, Blazer LL, Adams JJ, Srinivasan S, Moghisaei S, Sidhu SS, Siebold C, Ho HH.
    Elife; 2024 May 23; 13():. PubMed ID: 38780011
    [Abstract] [Full Text] [Related]

  • 35. Wnt5a/Ror2-induced upregulation of xPAPC requires xShcA.
    Feike AC, Rachor K, Gentzel M, Schambony A.
    Biochem Biophys Res Commun; 2010 Oct 01; 400(4):500-6. PubMed ID: 20732301
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.